Imgn289
EGFR Positive Solid Tumors
ImmunoGen, Inc.Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the EGFR Positive Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Vir Biotechnology, Inc. | Phase 1 | CC |
Cyclophosphamide Vir Biotechnology, Inc. | Phase 1 | CC |
Vir-5525 Vir Biotechnology, Inc. | Phase 1 | CC |
Epirubicin Vir Biotechnology, Inc. | Phase 1 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →